GlassScriptPhysician profile
Fernando J Cabrera
NPI 1891957080
$5,643.08
in general payments reported to CMS, 2019-2025
28 companies · $970 in 2025
The $970 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,198 · 2020: $788 · 2021: $958 · 2022: $761 · 2023: $499 · 2024: $470 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591 · Travel and Lodging: $247 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.36 |
| Travel and Lodging | $247.47 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $1,129.31 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $567.57 | 2019-2025 | Bard Urinary Drainage Bag |
| Janssen Biotech, INC. | $545.98 | 2019-2025 | Erleada |
| Procept Biorobotics Corporation | $540.32 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Neotract INC. | $436.01 | 2019 | |
| Myriad Genetic Laboratories, INC. | $407.87 | 2022-2025 | Prolaris, Myrisk |
| Boston Scientific Corporation | $377.43 | 2019-2025 | General - Erectile Dysfunction |
| Astellas Pharma US INC | $374.99 | 2019-2023 | Myrbetriq |
| Olympus America INC. | $196.89 | 2019-2022 | |
| Becton, Dickinson and Company | $168.00 | 2024 | Bard Urinary Drainage Bag |
| Coloplast Corp | $162.87 | 2021-2024 | Speedicath |
| Urogen Pharma, INC. | $159.76 | 2022-2025 | Jelmyto |
| Richard Wolf Medical Instruments Corp. | $145.85 | 2019 | |
| Bard Access Systems, INC. | $54.73 | 2019 | |
| Convatec INC. | $53.12 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.82 | 2022-2025 | Keytruda, Welireg |
| Tolmar Pharmaceuticals, INC. | $42.40 | 2021-2022 | |
| Calyxo, INC. | $32.44 | 2025 | Cvac Aspiration System |
| Sumitomo Pharma America, INC. | $28.04 | 2025 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $24.36 | 2022 | |
| Teleflex LLC | $23.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.95 | 2025 | |
| Verity Pharmaceuticals INC. | $19.97 | 2025 | Tlando |
| Laborie Medical Technologies Corp. | $19.37 | 2022 | |
| Abbvie INC. | $17.31 | 2025 | |
| Tolmar, INC. | $15.76 | 2024 | |
| Acerus Pharmaceuticals Corporation | $14.72 | 2021 | |
| Medtronic, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.